Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
TOP
Print Edition
We will request your mailing address on the next page.
TOP
E-Newsletters and Communications
JHOP
Print Edition
We will request your mailing address on the next page.
JHOP
E-Newsletters and Communications
I have reviewed and consent to the terms of
TOP
's
Privacy Policy
, and
TOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe
Home
Issues
2021
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
2018
November 2018 - Vol 11 No 3
August 2018 - Vol 11 No 2
May 2018 - Vol 11 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Year End Review 2019
Web Exclusives
Ovarian Cancer Overview
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Interview with the Innovators
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Charles Bankhead
Authored Items
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2
in
Colorectal Cancer
Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2
in
Immunotherapy
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
Charles Bankhead
Web Exclusives
in
Emerging Therapies
New BTK Inhibitor Leads to Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia
Charles Bankhead
Web Exclusives
in
Leukemia
High Response Rate with 3-Drug Combination for Untreated Follicular Lymphoma
Charles Bankhead
Web Exclusives
in
Lymphoma
Chemotherapy Use in Breast Cancer Declines with Use of MammaPrint Gene-Based Assay
Charles Bankhead
TOP - November 2016, Vol 9, No 4
in
Breast Cancer
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Charles Bankhead
TOP - May 2016, Vol 9, No 2
in
Genitourinary Cancers
More Bad News for Erythropoiesis-Stimulating Agents in Chemotherapy-Induced Anemia
Charles Bankhead
TOP - May 2015, Vol 8, No 2
in
Breast Cancer
Highest Response Rate to Date in mRCC With Pazopanib as Third-Line VEGF Inhibitor
Charles Bankhead
TOP - October 2014, Vol 7, No 4
in
Genitourinary Cancers
PARP Inhibitor Veliparib Active in Recurrent BRCA-Positive Ovarian Cancer
Charles Bankhead
TOP - October 2014, Vol 7, No 4
in
Gynecologic Cancers
Last modified: December 11, 2015
Home
Issues
2021
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
2018
November 2018 - Vol 11 No 3
August 2018 - Vol 11 No 2
May 2018 - Vol 11 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Year End Review 2019
Web Exclusives
Ovarian Cancer Overview
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Interview with the Innovators
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines